164 related articles for article (PubMed ID: 28012025)
1. Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model.
El-Demerdash E; Abdel-Sattar SA; El-Bakly WM; Mohamed EA
Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):767-779. PubMed ID: 28012025
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage.
Hamdy N; El-Demerdash E
Toxicol Appl Pharmacol; 2012 Jun; 261(3):292-9. PubMed ID: 22543095
[TBL] [Abstract][Full Text] [Related]
3. Carvedilol suppresses circulating and hepatic IL-6 responsible for hepatocarcinogenesis of chronically damaged liver in rats.
Balaha M; Kandeel S; Barakat W
Toxicol Appl Pharmacol; 2016 Nov; 311():1-11. PubMed ID: 27746314
[TBL] [Abstract][Full Text] [Related]
4. Anti-fibrotic impact of Carvedilol in a CCl-4 model of liver fibrosis via serum microRNA-200a/SMAD7 enhancement to bridle TGF-β1/EMT track.
El-Wakeel SA; Rahmo RM; El-Abhar HS
Sci Rep; 2018 Sep; 8(1):14327. PubMed ID: 30254303
[TBL] [Abstract][Full Text] [Related]
5. Carvedilol Attenuates the Progression of Hepatic Fibrosis Induced by Bile Duct Ligation.
Tian X; Zhao C; Guo J; Xie S; Yin F; Huo X; Zhang X
Biomed Res Int; 2017; 2017():4612769. PubMed ID: 28396867
[No Abstract] [Full Text] [Related]
6. Deferoxamine alleviates liver fibrosis induced by CCl4 in rats.
Mohammed A; Abd Al Haleem EN; El-Bakly WM; El-Demerdash E
Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):760-8. PubMed ID: 27168353
[TBL] [Abstract][Full Text] [Related]
7. Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion.
Muñoz-Ortega MH; Llamas-Ramírez RW; Romero-Delgadillo NI; Elías-Flores TG; Tavares-Rodríguez Ede J; Campos-Esparza Mdel R; Cervantes-García D; Muñoz-Fernández L; Gerardo-Rodríguez M; Ventura-Juárez J
Gut Liver; 2016 Jan; 10(1):101-8. PubMed ID: 26573293
[TBL] [Abstract][Full Text] [Related]
8. A Targeted Multiple Antigenic Peptide Vaccine Augments the Immune Response to Self TGF-β1 and Suppresses Ongoing Hepatic Fibrosis.
Li Y; Wang W; Jia X; Zhai S; Wang X; Wang Y; Dang S
Arch Immunol Ther Exp (Warsz); 2015 Aug; 63(4):305-15. PubMed ID: 25740471
[TBL] [Abstract][Full Text] [Related]
9. Effect of ginseng extract on the TGF-β1 signaling pathway in CCl
Hafez MM; Hamed SS; El-Khadragy MF; Hassan ZK; Al Rejaie SS; Sayed-Ahmed MM; Al-Harbi NO; Al-Hosaini KA; Al-Harbi MM; Alhoshani AR; Al-Shabanah OA; Alsharari SD
BMC Complement Altern Med; 2017 Jan; 17(1):45. PubMed ID: 28086769
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Effect of Citalopram on the Pharmacokinetics of Carvedilol in Rats and in vitro Models.
Abrudan MB; Muntean DM; Popa DS; Gheldiu AM; Neag MA; Vlase L
Pharmacology; 2017; 100(5-6):301-307. PubMed ID: 28848215
[TBL] [Abstract][Full Text] [Related]
12. Hepatoprotective Effects of Grape Seed Procyanidin B2 in Rats With Carbon Tetrachloride-induced Hepatic Fibrosis.
Wang Z; Zhang Z; Du N; Wang K; Li L
Altern Ther Health Med; 2015; 21 Suppl 2():12-21. PubMed ID: 26308756
[TBL] [Abstract][Full Text] [Related]
13. The Pharmacokinetic Interaction Study between Carvedilol and Bupropion in Rats.
Abrudan MB; Muntean DM; Gheldiu AM; Neag MA; Vlase L
Pharmacology; 2017; 99(3-4):139-143. PubMed ID: 28052289
[TBL] [Abstract][Full Text] [Related]
14. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
15. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics.
Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H
Chirality; 1993; 5(1):1-7. PubMed ID: 8095396
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of Ginkgo biloba, Panax ginseng, and Schizandra chinensis extract on liver injury in rats.
Chang HF; Lin YH; Chu CC; Wu SJ; Tsai YH; Chao JC
Am J Chin Med; 2007; 35(6):995-1009. PubMed ID: 18186586
[TBL] [Abstract][Full Text] [Related]
17. Mistletoe alkaloid fractions alleviates carbon tetrachloride-induced liver fibrosis through inhibition of hepatic stellate cell activation via TGF-β/Smad interference.
Jiang Y; Wang C; Li YY; Wang XC; An JD; Wang YJ; Wang XJ
J Ethnopharmacol; 2014 Dec; 158 Pt A():230-8. PubMed ID: 25456431
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of extracts from Pomegranate peels and seeds on liver fibrosis induced by carbon tetrachloride in rats.
Wei XL; Fang RT; Yang YH; Bi XY; Ren GX; Luo AL; Zhao M; Zang WJ
BMC Complement Altern Med; 2015 Oct; 15():389. PubMed ID: 26508316
[TBL] [Abstract][Full Text] [Related]
19. Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl₄-treated rats.
Clichici S; Olteanu D; Nagy AL; Oros A; Filip A; Mircea PA
J Med Food; 2015 Mar; 18(3):290-8. PubMed ID: 25133972
[TBL] [Abstract][Full Text] [Related]
20. Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis by olmesartan and omega-3.
Shaaban AA; Shaker ME; Zalata KR; El-kashef HA; Ibrahim TM
Chem Biol Interact; 2014 Jan; 207():81-91. PubMed ID: 24144775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
